Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Summit Therapeutics (SMMT) Other Accumulated Expenses (2019 - 2025)

Summit Therapeutics' Other Accumulated Expenses history spans 7 years, with the latest figure at $2.0 million for Q3 2025.

  • For Q3 2025, Other Accumulated Expenses rose 90.46% year-over-year to $2.0 million; the TTM value through Sep 2025 reached $2.0 million, up 90.46%, while the annual FY2024 figure was $1.8 million, 150.63% up from the prior year.
  • Other Accumulated Expenses reached $2.0 million in Q3 2025 per SMMT's latest filing, up from $1.5 million in the prior quarter.
  • In the past five years, Other Accumulated Expenses ranged from a high of $2.0 million in Q3 2025 to a low of $209000.0 in Q3 2022.
  • Average Other Accumulated Expenses over 5 years is $828473.7, with a median of $717000.0 recorded in 2023.
  • Peak YoY movement for Other Accumulated Expenses: soared 190.96% in 2021, then plummeted 79.71% in 2022.
  • A 5-year view of Other Accumulated Expenses shows it stood at $897000.0 in 2021, then dropped by 26.2% to $662000.0 in 2022, then increased by 8.31% to $717000.0 in 2023, then surged by 150.63% to $1.8 million in 2024, then increased by 8.85% to $2.0 million in 2025.
  • Per Business Quant, the three most recent readings for SMMT's Other Accumulated Expenses are $2.0 million (Q3 2025), $1.5 million (Q2 2025), and $759000.0 (Q1 2025).